October 6–7 | Abu Dhabi
Dr. Alex Aliper, Co-founder and President of Insilico Medicine, has been invited to speak at the AI Everything Abu Dhabi summit. He will join a panel discussion titled "The Machines Curing Us" on October 6 from 2:00 PM to 2:30 PM at the T3 Frontier stage at the ADNEC Center Abu Dhabi.
As one of the premier global events in artificial intelligence, AI Everything convenes government policymakers, tech giants, startups, top investment firms, and R&D leaders from around the world. Discussions will focus on cutting-edge topics including Generative AI, AI agents, and AI for Science. Dr. Alex Aliper will engage with key players in the global AI ecosystem to showcase Insilico Medicine’s latest advances in LLM-driven drug discovery, autonomous robotics labs, and interdisciplinary scientific breakthroughs, exploring how intelligent systems are reshaping novel drug discovery, pushing human biological limits, and extending healthy lifespan.
About AI Everything Abu Dhabi
AI Everything is one of the world's most influential AI event series. As the flagship AI event under the GITEX GLOBAL brand organized by KAOUN International (a subsidiary of Dubai World Trade Centre), it attracts tens of thousands of attendees from over 150 countries. Attendees include government officials developing national AI strategies, enterprise operators driving industrial transformation, and global companies seeking cutting-edge technological solutions. It serves as a central platform for global dialogue on AI policy, investment, and industrial applications, as well as a vital window into the Middle East's emerging AI economy.
October 7–9 | Yokohama, Japan
Insilico Medicine will make an appearance at BioJapan 2026 , held from October 7 to 9 at PACIFICO Yokohama, at Booth D74 . Insilico’s Business Development team will be on-site to engage in face-to-face meetings with attendees and potential partners. We look forward to discussing emerging trends in AI-driven drug discovery, sharing practical insights on generative AI across the entire drug development lifecycle, and exploring multifaceted strategic partnering opportunities.
Leveraging BioJapan’s proprietary 1-on-1 partnering system, Insilico Medicine will participate in intensive partnering meetings with global biopharmas, biotech companies, and research institutions. Discussions will cover platform licensing, co-development, and asset transactions, further expanding the company’s strategic partner network in the Asia-Pacific region.
About BioJapan 2026
Founded in 1986, BioJapan is Asia's oldest and largest premier biotechnology event. The 2026 edition will take place from October 7 to 9 at PACIFICO Yokohama.
The event convenes global pharmaceutical leaders, innovative biotech companies, renowned academic institutions, and investors, focusing on frontier areas such as generative AI for drug discovery, cell and gene therapy, precision oncology, and longevity biology. Through its open innovation platform, BioJapan connects global pharma with Asian innovation sources, serving as a key benchmark for expanding global life science footprints and forging strategic licensing and R&D partnerships.
October 7–11 | San Francisco
Dr. Alex Zhavoronkov, Founder and Co-CEO of Insilico Medicine, has been invited to attend the Abundance Longevity Trip , founded by Dr. Peter Diamandis. He will deliver a presentation titled "Cracking the Code of Life with AI - Using Frontier AI to Develop Longevity Therapeutics" on October 8 from 2:55 PM to 3:25 PM.
As a recognized thought leader in aging research and longevity biotechnology, Dr. Zhavoronkov will join top global longevity scientists and biotech founders. Drawing from Insilico's pioneering breakthroughs, he will share insights into AI biology of aging, anti-aging interventions, and longevity drug discovery, joining fellow delegates to usher in a new era of AI-driven longevity medicine.
About Abundance Longevity Trip
Organized by Dr. Peter Diamandis, founder of the XPRIZE Foundation and New York Times bestselling author, the Abundance Longevity Trip is an exclusive, 5-day immersive longevity science experience limited to just 80 members. Since 2020, the trip has gathered over 50 top longevity scientists—including Nobel laureates, Harvard researchers, and biotech pioneers. The curriculum covers cutting-edge topics such as CRISPR and epigenetic reprogramming, cellular therapeutics, organ regeneration, AI-driven drug discovery, advanced diagnostics and biomarkers, as well as senolytics and longevity therapeutics. Featuring private visits to top research labs and personalized health optimization protocols, it is widely recognized as the most exclusive convergence of longevity science, thought leadership, and investment.
https://longevity.abundance360.com/
About Insilico Medicine
Insilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life sciences, and extend healthy longevity to people on the planet. The company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code 03696.HK.
By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma. AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine.
For more information, please visit www.insilico.com